8. 5-Flurouracil Capsules and Injections.

9. Ftorafur Injection and Capsules.

10. Hydroxyurea Capsules.

11. L-Asparaginast (Colaspase) Injection.

12. Levodopa (L-Dopa) Tablets/ Capsules.

13. Lomustine (CCNU).

14. Melphalan Tablets and Injection.

15. Mercaptopurine Tablets.

16. Methotrexate Tablets and Injection.

17. Mitomycine C Injection and Capsules.

18. Mustine Hydrochloride Injection.

19. Tamoxifen Citrate Tablets.

20. Thotepa Injection.

21. Vinblastrine Sulphate Injection.

22. Vincristrine Sulphate Injection.

De-Registered Companies under the MRTP Act

*255. SHRI YALLA SESI BHUSHANA RAO:
PROF. C. LAKSHMANNA:

Will the Minister of INDUSTRY be pleased to state:

(a) whether a number of companies have got de-registered under the MRTP Act after the increase in the asset limit from Rs 20 crores to 100 crores; and

(b) if so, what are the companies that have got out of the purview of the Act and which were the Industrial Groups with which they were connected before the de-registration?

THE MINISTER OF INDUSTRY AND MINISTER OF PETROLEUM AND NATURAL GAS (SHRI NARAYAN DATT TIWARI): (a) Yes, Sir.

(b) A statement is laid on the Table of the House. [*See* Appendix CXXXIX Annexure No. 77].

Use of Solar Energy

*256. SHRI J. P. GOYAL: Will the Minister of ENERGY be pleased to state:

(a) in what ways solar energy has been put to use in the country so far; and

(b) what steps have been taken by Government to popularise the use of solar energy?

THE MINISTER OF ENERGY (SHRI VASANT SATHE): (a) Solar Energy through the thermal and photovoltaic routes is now being used in the country for a variety of applications such as cooking, water heating, air heating, wood seasoning, drying of farm products, purification of brackish water, conditioning of living space, storage of perishable material for low temperature, generation of power, operation of street lights, television, radio, water pumping; signalling, telecommunication etc.

(b) Steps have been taken to popularise the use of solar energy devices including technical support, subsidies and other fiscal incentives for construction/installation, arranging demonstration programmes, training programmes for users, spread of awarnesses through seminars, symposia, radio and television, accelerated use through Central and State Nodal Agencies as well as voluntary organisations. Efforts are being continued to extend the coverage of the existing programmes to more areas and also to further reduce costs and improve efficiencies of these devices through R and D.

New Drug Policy

*257. DR. BAPU KALDATE: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that a Committee of Secretaries to the Government has been consideraing the new drug policy;

(b) whether it is also a fact that the delay in finalisation of the new drug policy has hampered the growth of the drug industry; and